Sensei Biotherapeutics board unanimously rejects Newtyn's $1.00/share takeover bid

Sensei Biotherapeutics, Inc.

Received unsolicited proposal from Newtyn Management to acquire all shares at $1.00/share in cash.
Board unanimously determined proposal substantially undervalues the company and its future prospects.
Company believes it is well-positioned to execute strategy and create long-term value for stockholders.
Rejection formalized on November 6, 2023; no further terms disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.